Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475

Journal of Neurology Neurosurgery and Psychiatry

Volumn 73, Issue 6, 2002, Pages 678-685

  Rosser, A E ^a,b   Barker, R A ^b   Harrower, T ^b   Watts, C ^b   Farrington, M ^b   Ho, A K ^b   Burnstein, R M ^b   Menon, D K ^b   Gillard, J H ^b   Pickard, J ^b   Dunnett, S B ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; PREDNISOLONE;

ADULT; ARTICLE; CELL SUSPENSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG SAFETY; FETAL TISSUE TRANSPLANTATION; FETUS; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; MACROCYTIC ANEMIA; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; STEREOTAXIC SURGERY; TISSUE GROWTH;

ADULT; BRAIN TISSUE TRANSPLANTATION; CLINICAL TRIALS DATA MONITORING COMMITTEES; CORPUS STRIATUM; DOMINANCE, CEREBRAL; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMAN; HUNTINGTON DISEASE; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MOTOR SKILLS; NEUROPSYCHOLOGICAL TESTS; POSTOPERATIVE COMPLICATIONS; STEREOTAXIC TECHNIQUES; SUPPORT, NON-U.S. GOV'T; TRANSPLANTATION;

EID: 0036904801     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.73.6.678     Document Type: Article

References (52)

1. Harper PS. Huntington's Disease. 2nd Ed. London: W B Saunders, 1996.
2. Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-77.
3. Huntington's disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83.
4. Ho LW, Carmichael J, Swartz J, et al. The molecular biology of Huntington's disease. Psychol Med 2001;31::3-14.
5. Li XJ. The early cellular pathology of Huntington's disease. Mol Neurobiol 2000;20:111-24.
6. Gutekunst CA, Norflus F, Hersch SM. Recent advances in Huntington's disease. Curr Opin Neurol 2000;13:445-50.
7. Lunkes A, Trottier Y, Mandel JL. Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases. Essays Biochem 1998;33:149-63.
8. Aronin N, Kim M, Laforet G, et al. Are there multiple pathways in the pathogenesis of Huntington's disease? Philos Trans R Soc Lond B Biol Sci 1999;354:995-1003.
9. Kieburtz K. Antiglutamate therapies in Huntington's disease. J Neural Transm Suppl 1999;55:97-102.
10. Huntington's Disease Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
11. Peschanski M, Cesaro P, Hantraye P. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 1995;68:273-285.
12. Lindvall O. Neural transplantation: A hope for patients with Parkinson's disease. Neuroreport 1997;8:iii-x.
13. Peschanski M. Treatment of neurodegenerative diseases. Pathol Biol (Paris) 2000;48:447-8.
14. Björklund A, Campbell K, Sirinathsinghji DJS, et al. Functional capacity of striatal transplants in the rat Huntington model. In: Dunnett SB, Bjorklund A, eds. Functional Neural Transplantation. New York: Raven Press, 1994:157-95.
15. Brasted PJ, Watts C, Torres EM, et al. Behavioural recovery following striatal transplantation: Effects of postoperative training and P-zone volume. Exp Brain Res 1999;128:535-8.
16. Kendall AL, Rayment FD, Torres EM, et al. Functional integration of striatal allografts in a primate model of Huntington's disease. Nat Med 1998;4:727-9.
17. Palfi S, Conde F, Riche D, et al. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med 1998;4:963-6.
18. Kopyov OV, Jacques S, Kurth M, et al. Fetal transplantation for Huntington's disease: Clinical studies. In: Freeman TB, Widner H, eds. Cell Transplantation for Neurological Disorders. Totowa: Humana Press, 1998:95-134.
19. Freeman TB, Hauser RA, Sanberg PR, et al. Neural transplantation for the treatment of Huntington's disease. Prog Brain Res 2000;127:405-11.
20. Ulrisch R, Jacques S, Kopyov O. Neural transplantation. J Neurosurg 2000;93:163-4.
21. Rosser AE, Dunnett SB. Neural transplantation for the treatment of Huntington's disease. In: Krauss JK, Jankovic J, Grossman RG, eds. Movement Disorders Surgery. New York: Lippinicott Williamns and Wilkins 2001:353-73.
22. Dunnett SB, Rosser AE. Cell and tissue transplantation. In: Harper P, Jones L, Bates G, eds. Huntington's Disease, 3rd Edn. Oxford: Oxford University Press (in press).
23. Bachoud-Levi A, Bourdet C, Brugieres P, et al. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol 2000;161:194-202.
24. Kopyov OV, Jacques S, Lieberman A, et al. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 1998;149:97-108.
25. Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002;58:687-95.
26. Freeman TB, Cicchetti F, Hauser RA, et al. Transplanted fetal striatum in Huntington's disease: Phenotypic development and lack of pathology. Proc Natl Acad Sci USA 2000;97:13877-82.
27. Dunnett SB, Björklund A, Lindvall O. Cell therapy in Parkinson's disease - Stop or go? Nature Neuroscience Reviews 2001;2:365-9.
28. Bachoud-Levi AC, Remy P, Nguyen JP, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000;356:1975-9.
29. Folkerth RD, Durso R. Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Neurology 1996;46:1219-25.
30. Mamelak AN, Faye A, Edderding MD, et al. Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinson's disease. J Neurosurgery 1998;89:592-8.
31. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-19.
32. Macklin R. The ethical problems with sham surgery in clinical research. N Engl J Med 1999;341:992-6.
33. Dekkers W, Boer G. Sham neurosurgery in patients with Parkinson's disease: Is it morally acceptable? J Med Ethics 2001;27:151-6.
34. Quinn N, Brown R, Craufurd D, et al. Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). Mov Disord 1996;11:143-50.
35. Rosser AE, Barker RA, Elneil S, et al. Staging and preparation of human fetal striatal tissue for UK study of neural transplantation in Huntington's disease ISRCTN no 36485475. Cell Transplantation (in press).
36. Widner H, Tetrud J, Rehncrona S, et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1992;327:1556-63.
37. Peschanski M, Defer G, N'Guyen JP, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994;117:487-99.
38. Polkinghorne J, Hoffenberg R, Kennedy I, et al. Review of the guidance on the research use of fetuses and fetal material. Parliamentary Committee, 1989.
39. Department of Health. Guidance on the Supply of Fetal Tissue for Research, Diagnosis and Therapy. London: Department of Health, 1989.
40. Hurelbrink CB, Armstrong RJ, Barker RA, et al. Hibernated human fetal striatal tissue: Successful transplantation in a rat model of Huntington's disease. Cell Transplantation 2000;9:743-9.
41. Hurelbrink CB, Tyers P, Armstrong RJE, et al. Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: Implications for clinical trials in Huntington's disease ISRCTN no 36485475. Cell Transplantation (in press).
42. Watts C, Donovan T, Gillard JH, et al. Evaluation of an MRI-based protocol for cell implantation in four patients with Huntington's disease ISRCTN no. 36485475. Cell Transplantation (in press)
43. Lindvall O, Widner H, Rehncrona S, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: One-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992;31:155-65.
44. Huntington's Disease Study Group. Unified Huntington's disease rating scale: Reliability and consistency. Mov Disord 1996;11:136-42.
45. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
46. Lawrence AD, Hodges JR, Rosser AE, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998;121:1329-41.
47. Ross BD, Hoang TQ, Bluml S, et al. In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed 1999;12:221-36.
48. Freeman TB, Kordower JH. Human cadaver embryonic substantia nigra grafts: Ontogeny, perioperative graft preparation and tissue storage. In: Lindvall O, Björklund A, eds. Intracerebral Transplantation in Movement Disorders. Amsterdam: Elsevier Press, 1991:163-70.
49. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-24.
50. Grasbon-Frodl EM, Nakao N, Lindvall O, et al. Phenotypic development of the human embryonic striatal primordium: A study of cultured and grafted neurons from the lateral and medial ganglionic eminences. Neuroscience 1996;73:171-83.
51. Kendall AL, Hantraye P, Palfi S. Striatal tissue transplantation in non-human primates. Prog Brain Res 2000;127:381-404.
52. Wictorin K. Anatomy and connectivity of intrastriatal striatal transplants. Prog Neurobiol 1992;38:611-39.